AstraZeneca takes over key study from Achilles Therapeutics

In a significant step within oncology research, Achilles Therapeutics has transferred its commercial licensing of data and samples from the TRACERx study for non-small cell lung cancer research to AstraZeneca. TRACERx, led by Professor Charles Swanton from University College London, is considered one of the most comprehensive studies on tumor evolution. It provides in-depth sequencing data from various regions and time points from over 3,200 tumor samples collected from more than 800 lung cancer patients. As part of this transaction, AstraZeneca will also take on the role of sponsor for Achilles' Material Acquisition Platform (MAP). This platform is an exclusive network that has collected tumor tissue and blood from nearly 300 cancer patients who have undergone standard cancer surgery. This includes a variety of solid tumor indications, such as lung cancer, melanoma, as well as head and neck, kidney, bladder, and breast cancers. For the acquisition of the mentioned assets, AstraZeneca will pay Achilles Therapeutics a total of 12 million US dollars. This partnership promises to significantly advance the research and development of new treatment methods and open new horizons in the exploration of the genetic development of tumors.